• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国泰州 7-14 岁儿童中使用灭活 COVID-19 疫苗(科兴疫苗)的安全性。

Safety of an inactivated COVID-19 vaccine (CoronaVac) in children aged 7-14 years in Taizhou, China.

机构信息

Medical Postgratuate Degree, Department of General Surgery, The First People's Hospital of Jiande, Jiande, Zhejiang, PR China.

Medical Undergratuate Degree. Department of Operation, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, Zhejiang, PR China.

出版信息

Diagn Microbiol Infect Dis. 2024 Jun;109(2):116253. doi: 10.1016/j.diagmicrobio.2024.116253. Epub 2024 Mar 16.

DOI:10.1016/j.diagmicrobio.2024.116253
PMID:38507964
Abstract

Our study aimed to evaluate the safety of CoronaVac, an inactivated vaccine made by Sinovac, in children aged 7-14. We conducted a parent-administered online survey to monitor adverse reactions after vaccinating children in Taizhou, China, from February 15, 2021, to January 19, 2022. 767 parents completed the survey after receiving a questionnaire via WeChat. Overall, 15.3 % (117/767) of children experienced adverse effects after the first dose, and 12.2 % (88/724) after the second. Muscle pain was the most common adverse reaction post-first dose (10.0 %), while localized pain or itching at the injection site was most common after the second dose (7.6 %). In conclusion, the vaccine has a low incidence of side effects. The mild to moderate, transient, and common nature of these effects further boosts parents' confidence in vaccinating their children.

摘要

我们的研究旨在评估科兴新冠病毒灭活疫苗(克尔来福)在 7-14 岁儿童中的安全性。我们在中国泰州开展了一项家长在线调查,以监测自 2021 年 2 月 15 日至 2022 年 1 月 19 日为儿童接种疫苗后的不良反应。767 名家长在通过微信收到问卷后完成了调查。总体而言,15.3%(117/767)的儿童在接种第一针后出现了不良反应,12.2%(88/724)在接种第二针后出现了不良反应。肌肉疼痛是接种第一针后最常见的不良反应(10.0%),而接种第二针后最常见的不良反应是注射部位局部疼痛或瘙痒(7.6%)。总之,该疫苗的副作用发生率较低。这些不良反应的轻度至中度、短暂和常见性质进一步增强了家长对为儿童接种疫苗的信心。

相似文献

1
Safety of an inactivated COVID-19 vaccine (CoronaVac) in children aged 7-14 years in Taizhou, China.中国泰州 7-14 岁儿童中使用灭活 COVID-19 疫苗(科兴疫苗)的安全性。
Diagn Microbiol Infect Dis. 2024 Jun;109(2):116253. doi: 10.1016/j.diagmicrobio.2024.116253. Epub 2024 Mar 16.
2
Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China.中国医护人员中灭活 SARS-CoV-2 疫苗的安全性。
Expert Rev Vaccines. 2021 Jul;20(7):891-898. doi: 10.1080/14760584.2021.1925112. Epub 2021 May 13.
3
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一项在 18-59 岁健康成年人中进行的新型冠状病毒灭活疫苗的安全性、耐受性和免疫原性的随机、双盲、安慰剂对照、1/2 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17.
4
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.一项在健康儿童和青少年中进行的灭活 SARS-CoV-2 疫苗(科兴疫苗)的安全性、耐受性和免疫原性的双盲、随机、对照、1/2 期临床试验。
Lancet Infect Dis. 2021 Dec;21(12):1645-1653. doi: 10.1016/S1473-3099(21)00319-4. Epub 2021 Jun 28.
5
Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.医护人员中灭活 COVID-19 疫苗的安全性和免疫原性。
J Med Virol. 2022 Apr;94(4):1442-1449. doi: 10.1002/jmv.27458. Epub 2021 Nov 24.
6
The Actual Status of Hospitals as COVID-19 Vaccination Clinics in China and Safety Monitoring of Inactivated Vaccine: A Cross-Sectional Study.中国新冠疫苗接种点的实际现状和灭活疫苗的安全性监测:一项横断面研究。
Disaster Med Public Health Prep. 2022 Aug 26;17:e256. doi: 10.1017/dmp.2022.217.
7
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一种灭活严重急性呼吸综合征冠状病毒2疫苗(科兴新冠疫苗)在60岁及以上健康成年人中的安全性、耐受性和免疫原性:一项随机、双盲、安慰剂对照的1/2期临床试验
Lancet Infect Dis. 2021 Jun;21(6):803-812. doi: 10.1016/S1473-3099(20)30987-7. Epub 2021 Feb 3.
8
Safety of CoronaVac and ChAdOx1 vaccines against SARS-CoV-2 in patients with rheumatoid arthritis: data from the Brazilian multicentric study safer.CoronaVac 和 ChAdOx1 疫苗在类风湿关节炎患者中预防 SARS-CoV-2 的安全性:来自巴西多中心研究 safer 的数据。
Adv Rheumatol. 2024 Aug 12;64(1):58. doi: 10.1186/s42358-024-00397-5.
9
Adverse event following immunisation of adsorbed-inactivated Coronavac (Sinovac) and ChAdOx1 nCOV-19 (Astra Zeneca) of COVID-19 vaccines.接种 COVID-19 疫苗后吸附灭活型 Coronavac(科兴)和 ChAdOx1 nCOV-19(阿斯利康)的不良事件。
Med J Malaysia. 2024 Sep;79(5):507-511.
10
The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac -inactivated COVID-19 vaccines.既往 SARS-CoV-2 感染对 TURKOVAC 或科兴新冠病毒灭活疫苗接种者疫苗后不良事件的影响。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2346388. doi: 10.1080/21645515.2024.2346388. Epub 2024 Jun 26.

引用本文的文献

1
The Improvement of Adaptive Immune Responses towards COVID-19 Following Diphtheria-Tetanus-Pertussis and SARS-CoV-2 Vaccinations in Indonesian Children: Exploring the Roles of Heterologous Immunity.印度尼西亚儿童接种白喉-破伤风-百日咳疫苗和新冠病毒疫苗后对新冠病毒适应性免疫反应的改善:探索异源免疫的作用
Vaccines (Basel). 2024 Sep 9;12(9):1032. doi: 10.3390/vaccines12091032.